Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook
Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.
First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...
Hosted on MSN19h
Lundbeck gains FDA fast track designation for MSA therapy amlenetug
The designation will provide Lundbeck with the possibility of rolling reviews and detailed guidance to streamline the drug ...
Asklepios BioPharmaceutical, Inc. (AskBio): First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) ...
Hosted on MSN23h
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...
The American Journal of Managed Care20h
Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval
The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...
What happens in the brain when there's a word 'on the tip of the tongue'?
We've all experienced it: you're in the middle of a conversation, searching for a word, a name, or a title, and… nothing. You know you know it—you can almost feel it—but it just won't come. This ...
Study reveals immune system's crucial role in amyotrophic lateral sclerosis at cellular level
A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...
PIP payments of up to £737 each month for people with these muscle or joint conditions
More than one million people are receiving between £28.70 and £184.30 each week through PIP or Adult Disability Payment for ...
FiercePharma23h
Roche scores FDA nod for Evrysdi tablets, bolstering convenience edge over rivals
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
PipelineReview.com10h
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
SOUTH SAN FRANCISCO, CA, USA I 12, 2025 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug ...